Oppenheimer Asset Management Inc. Sells 3,418 Shares of Repligen Co. (NASDAQ:RGEN)

Oppenheimer Asset Management Inc. lessened its position in Repligen Co. (NASDAQ:RGEN) by 16.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 17,567 shares of the biotechnology company’s stock after selling 3,418 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Repligen were worth $2,529,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the company. Amalgamated Bank raised its holdings in Repligen by 1.0% in the 4th quarter. Amalgamated Bank now owns 25,114 shares of the biotechnology company’s stock worth $3,615,000 after acquiring an additional 238 shares during the period. Keeler Thomas Management LLC raised its holdings in Repligen by 68.9% in the 4th quarter. Keeler Thomas Management LLC now owns 8,979 shares of the biotechnology company’s stock worth $1,294,000 after acquiring an additional 3,662 shares during the period. Handelsbanken Fonder AB raised its holdings in Repligen by 8.9% in the 4th quarter. Handelsbanken Fonder AB now owns 14,633 shares of the biotechnology company’s stock worth $2,106,000 after acquiring an additional 1,200 shares during the period. Global Retirement Partners LLC raised its holdings in Repligen by 54.0% in the 4th quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company’s stock worth $53,000 after acquiring an additional 129 shares during the period. Finally, New York State Common Retirement Fund raised its holdings in Repligen by 2.5% in the 4th quarter. New York State Common Retirement Fund now owns 581,442 shares of the biotechnology company’s stock worth $83,693,000 after acquiring an additional 14,398 shares during the period. Institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

RGEN has been the topic of several research reports. JPMorgan Chase & Co. boosted their price objective on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. HC Wainwright restated a “buy” rating and set a $180.00 price objective on shares of Repligen in a report on Friday, February 21st. Canaccord Genuity Group boosted their price objective on shares of Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a report on Friday, February 21st. StockNews.com downgraded shares of Repligen from a “hold” rating to a “sell” rating in a report on Friday, February 21st. Finally, Royal Bank of Canada boosted their price objective on shares of Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a report on Friday, February 21st. One analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, Repligen presently has an average rating of “Moderate Buy” and a consensus target price of $181.00.

Repligen Price Performance

NASDAQ:RGEN opened at $159.26 on Monday. The firm has a market cap of $8.92 billion, a PE ratio of -312.27, a price-to-earnings-growth ratio of 4.54 and a beta of 0.99. Repligen Co. has a 12 month low of $113.50 and a 12 month high of $203.13. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The company’s 50-day moving average price is $156.17 and its two-hundred day moving average price is $148.56.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. The firm had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. On average, equities analysts anticipate that Repligen Co. will post 1.72 EPS for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.